ArticlePloS one2026
Novel approaches in linkage of data sources to explore the associations between purchase of opioid prescriptions during pregnancy and adverse neonatal outcomes.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate patterns of opioid purchases by payment source among pregnant women in Arkansas and examine their associations with adverse neonatal outcomes.
methodsLiveborn singleton infants born in Arkansas between 2014 and 2016 were identified from the Birth Certificate Records and linked to the All-Payer Claims Database (APCD), capturing public and private insurance claims; the Prescription Drug Monitoring Program (PDMP), recording controlled substance dispensations regardless of payment source; and the Social Determinants of Health Database, providing neighborhood socioeconomic indicators. Pregnancies were categorized as opioid non-buyers or buyers (insurance-only or self-paid). Adjusted odds ratios (AORs) for neonatal outcomes were estimated using Generalized Estimating Equations. Trimester-specific opioid exposure, expressed per 100 morphine milligram equivalents (MME), was analyzed to assess time-related effects.
resultsThis longitudinal retrospective cohort analysis included 27,441 pregnancies; 21% (5,841) involved opioid purchases, with 15% (880) including at least one self-paid transaction. Opioid prescription counts during pregnancy were 3,434 (PDMP), 2,161 (APCD), and 8,579 (both). Compared with non-buyers, opioid buyers had higher adjusted odds of preterm (PT) birth (AOR 1.14, 95% CI 1.02-1.27) and neonatal opioid withdrawal syndrome (NOWS) (AOR 2.10, 95% CI 1.42-3.11), with no significant associations observed for low birth weight, NICU admission, or birth-weight z-score. Increasing MME was associated with higher odds of NOWS in first (AOR 1.0045, 95% CI 1.0011-1.0080), second (AOR 1.0064, 95% CI 1.0025-1.0103), and third (AOR 1.0206, 95% CI 1.0122-1.0291) trimester. No significant differences were found between insurance-only and self-paid buyers for any neonatal outcome.
conclusionsLinking APCD and PDMP enabled a comprehensive assessment of prescribed opioid exposure. Opioid purchases were associated with increased risk of NOWS and modestly higher odds of PT birth. The dose and timing of opioid purchase were key determinants of NOWS. Payment source was not associated with differences in neonatal risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.